Ascentage Pharma (6855 HK), a leading biopharmaceutical company, has announced a significant development in its partnership strategy by signing an option agreement with Takeda Pharmaceutical Company Limited. This agreement grants Takeda the option to acquire exclusive global rights to develop and commercialize olverembatinib, a promising third-generation BCR-ABL tyrosine kinase inhibitor (TKI), outside of China and […]
Torrent Pharmaceuticals Limited has secured a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited to commercialize Vonoprazan, a novel potassium-competitive acid blocker (P-CAB), in India. This agreement marks a significant step forward in the treatment of acid-related disorders like Gastroesophageal Reflux Disease (GERD) within the Indian market. Torrent to Launch Vonoprazan Under the Trademark […]
Takeda Pharmaceutical Company announced positive results from its Phase 2b clinical trial for TAK-279, an investigational oral TYK2 inhibitor for treating psoriatic arthritis. Meeting its primary endpoint, the study confirmed that TAK-279 improved symptoms significantly better than a placebo at 12 weeks. This news supports TAK-279’s potential as a robust oral treatment for psoriatic arthritis […]
Takeda Pharmaceutical Company has revealed promising interim results from its global Phase 3 trial of TAK-755, a recombinant ADAMTS13 protein in development for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP). This makes TAK-755 the only recombinant ADAMTS13 protein under development, targeting an unmet medical need in TTP patients by replacing the missing or […]
Takeda Pharmaceutical Company has disclosed successful outcomes from its critical Phase 3 ADVANCE-CIDP 1 trial, focused on evaluating HYQVIA as a maintenance therapy for adults suffering from chronic inflammatory demyelinating polyneuropathy (CIDP). The study found a substantial decrease in relapse rates in patients treated with HYQVIA compared to those given a placebo (9.7% vs 31.4%, […]
Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary Hutchmed to strengthen its oncology portfolio. Under the licensing agreement, the Japanese pharmaceutical company will further develop and market the VEGFR1/2/3 tyrosine kinase inhibitor in all indications and territories outside of mainland China, Hong Kong, and Macau. […]
Takeda has received the European Commission’s (EC) marketing authorization for the company’s dengue vaccine QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). The QDENGA vaccine is indicated for use in individuals aged four and above in the European Union (EU) to prevent any of the four dengue serotypes. The approval from the EC was backed by […]
Strides Pharma Science Limited said that its Singapore-based stepdown fully-owned subsidiary — Strides Pharma Global Pte. Limited has secured approval for Colchicine Tablets USP, 0.6 mg from the US Food & Drug Administration (USFDA). Colchicine Tablets USP, 0.6 mg is bioequivalent and therapeutically equivalent to Colcrys Tablets, 0.6 mg, of Takeda Pharmaceuticals U.S.A. Colchicine tablets […]
Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed to meet the primary endpoint of progression-free survival (PFS). The late-stage trial assessed the combination of NINLARO (ixazomib) with lenalidomide and dexamethasone in comparison to lenalidomide and dexamethasone plus placebo […]
Takeda Pharmaceutical has agreed to sell a portfolio of certain non-core prescription pharma products sold mainly in Europe and Canada to German pharma company Cheplapharm for about $562 million. The portfolio to be offloaded to Cheplapharm is made up of non-core prescription pharma products in a range of therapeutic segments. This includes cardiovascular/metabolic and anti-inflammatory […]